| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RGS19 |
| Uniprot No | P49795 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-217aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMPTPHEAEKQITGPEEADRPPSMSSHDTAS PAAPSRNPCCLCWCCCCSCSWNQERRRAWQASRESKLQPLPSCEVCATPS PEEVQSWAQSFDKLMHSPAGRSVFRAFLRTEYSEENMLFWLACEELKAEA NQHVVDEKARLIYEDYVSILSPKEVSLDSRVREGINKKMQEPSAHTFDDA QLQIYTLMHRDSYPRFLSSPTYRALLLQGPSQSSSEA |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于RGS19重组蛋白的参考文献示例(注：文献为示例性概括，具体内容需根据实际论文调整)：
---
1. **文献名称**: "Regulation of G protein signaling by RGS19: expression, purification, and functional analysis"
**作者**: Hollinger, S. et al.
**摘要**: 研究报道了RGS19重组蛋白在大肠杆菌中的高效表达与纯化方法，并验证其通过GTP酶激活蛋白(GAP)活性负调控Gα亚基信号传导的功能，为体外研究RGS19的分子机制提供了工具。
2. **文献名称**: "Structural insights into RGS19-mediated G protein inhibition"
**作者**: Siderovski, D.P. et al.
**摘要**: 通过X射线晶体学解析了RGS19重组蛋白与Gαi亚基的复合物结构，揭示了其通过保守的RGS结构域加速Gαi的GTP水解，进而终止下游信号通路的分子机制。
3. **文献名称**: "RGS19 suppresses tumorigenesis by modulating Akt signaling in breast cancer cells"
**作者**: Kim, J.Y. et al.
**摘要**: 利用重组RGS19蛋白进行体外实验，证明其过表达通过抑制Akt信号通路降低乳腺癌细胞增殖和迁移能力，提示RGS19可能作为肿瘤治疗的新靶点。
---
如需具体文献，建议在PubMed或Web of Science中搜索关键词“RGS19 recombinant”或结合研究领域进一步筛选。
RGS19 (Regulator of G-protein Signaling 19) is a member of the RGS protein family, which plays a critical role in modulating G-protein-coupled receptor (GPCR) signaling pathways. As a GTPase-activating protein (GAP), RGS19 accelerates the hydrolysis of GTP bound to Gα subunits of heterotrimeric G proteins, thereby terminating signaling cascades initiated by GPCRs. This regulatory function positions RGS19 as a key player in cellular processes such as cell proliferation, differentiation, and immune responses. Its expression is observed in various tissues, with notable roles in the nervous, cardiovascular, and immune systems.
The recombinant RGS19 protein, produced through expression systems like *E. coli* or mammalian cells, retains the functional domain responsible for GAP activity. This engineered protein has become a valuable tool for studying GPCR signaling dynamics, drug discovery, and disease mechanisms. Researchers utilize it to investigate interactions with Gα subunits, screen for potential therapeutic compounds targeting RGS-G protein interfaces, and explore structural characteristics through techniques like X-ray crystallography. Notably, RGS19 has been implicated in cancer progression, neurodevelopmental disorders, and autoimmune diseases, with studies suggesting its dual role as both tumor suppressor and oncogene depending on cellular context.
Recent studies highlight RGS19's involvement in T-cell activation and immune tolerance, linking it to inflammatory diseases and immunotherapy research. Its recombinant form enables *in vitro* reconstitution of signaling pathways and validation of CRISPR-edited cellular models. As GPCR-targeted drugs represent ~30% of clinical therapeutics, understanding RGS19's regulatory mechanisms through recombinant protein studies holds significant therapeutic potential. Current challenges include elucidating post-translational modifications and tissue-specific interactions that modulate its activity *in vivo*.
×
